Cancer Genetics Inc (CGIX) 7.83 $CGIX
Cancer Genetics Inc. Granted Patent for Genomic Probe Set Used in Proprietary Test for Cervical and Other HPV-Associated Cancers
GlobeNewswire - Tue Oct 21, 6:59AM CDT
> Issuance of patent 8,865,882 covers four probe set used in CGI's proprietary FISH-based HPV-Associated Cancer Test (FHACT(R))
CGIX: 7.83 (+0.84)
Cancer Genetics Inc. Announces Collaboration With Leading Oncology Researchers at Columbia University to Identify Genomic Signatures, Biomarkers and Novel Treatments for MDS and AML
GlobeNewswire - Mon Oct 13, 6:45AM CDT
> The collaboration will result in a novel, next-generation sequencing based panel for the improved diagnosis and prognosis of Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)
CGIX: 7.83 (+0.84)
Global Genetic Testing Market - Industry Analysis And Market Forecast 2014-2020
PR Newswire - Thu Oct 09, 2:50PM CDT
Genetic testing is the analysis of genes, chromosomes, or proteins to help predict the risk of disease, identify carriers (individuals who do not have the disease but have a copy of the disease gene) of disease, diagnose disease, or determine the likely course of a disease. Cytogenetics, Molecular Genetics, Cancer Genetics, Prenatal Screening and Prenatal diagnosis are type of genetic tests that involves examining a person's genetic material taken from cells in a sample of blood or, occasionally, from other body fluids or tissues.
CGIX: 7.83 (+0.84)
Cancer Genetics Inc. to Provide Updates About the Company's Portfolio of Targeted Molecular Diagnostics at Analyst Day on September 25, 2014
GlobeNewswire - Wed Sep 24, 6:45AM CDT
Cancer Genetics Inc. (Nasdaq:CGIX) ("CGI" or "the Company"
, an emerging leader in DNA-based cancer diagnostics, today released an agenda for its upcoming Analyst Day, to be held Thursday, September 25 in Raleigh, North Carolina.
CGIX: 7.83 (+0.84)
Cancer Genetics, Inc. and Beth Israel Deaconess Medical Center Enter Into Collaboration to Correlate Genomic Profiles to Patient Outcome in Diffuse Large B-Cell Lymphoma
GlobeNewswire - Tue Sep 23, 6:45AM CDT
-- Study will correlate genetic markers to outcome in ~200 patients with diffuse large B-cell lymphoma (DLBCL), the most common form of non-Hodgkin lymphoma.
CGIX: 7.83 (+0.84)
Cancer Genetics, Inc. to Present at Aegis Healthcare and Technology Conference on Thursday, September 11, 2014
GlobeNewswire - Wed Sep 10, 6:59AM CDT
Cancer Genetics, Inc. (Nasdaq:CGIX) ("CGI" or "The Company" , an emerging leader in DNA-based cancer diagnostics, announced today that Panna Sharma will present at the Aegis Healthcare and Technology Conference on Thursday, September 11, 2014 at 8:30 am Pacific Daylight Time (11:30 am EDT).
CGIX: 7.83 (+0.84)
Cancer Genetics' Proprietary IVD for Cervical Cancer, FHACT(R), Receives CE
GlobeNewswire - Tue Sep 02, 7:15AM CDT
- Cancer Genetics, Inc. (Nasdaq:CGIX) ("CGI" or "The Company" , an emerging leader in DNA-based cancer diagnostics, announced today that their proprietary DNA-probe based test for cervical cancer (FHACT(R)) has received the CE Marking.
CGIX: 7.83 (+0.84)
Cancer Genetics' Proprietary Genomic Diagnostic Tests Added to National Institutes of Health's Genetic Testing Registry
GlobeNewswire - Wed Aug 27, 6:59AM CDT
-- Online database allows clinicians and patients to search for genetic and genomic tests by disease state
CGIX: 7.83 (+0.84)
Cancer Genetics, Inc. and Leading Pathologist From Keck Medicine of USC Collaborate to Evaluate and Optimize Genomic Panel for Lymphoma
GlobeNewswire - Mon Aug 25, 7:30AM CDT
-- Collaboration will identify and evaluate new genomic markers for most common form of non-Hodgkin's lymphoma
CGIX: 7.83 (+0.84)
Cancer Genetics Inc. Completes Acquisition of BioServe India, a Premier Genomics and Next-Generation Sequencing Company
GlobeNewswire - Sun Aug 17, 11:00PM CDT
-- Cancer Genetics Now Positioned to Participate in High-Growth Indian Diagnostics Market, Where More Than 1 Million New Cancer Cases Are Diagnosed Each Year
CGIX: 7.83 (+0.84)
Cancer Genetics Reports Second Quarter 2014 Financial Results
GlobeNewswire - Thu Aug 14, 6:05AM CDT
Cancer Genetics, Inc. (Nasdaq:CGIX), an emerging leader in DNA-based cancer diagnostics, announced today financial results for the second quarter and six months ended June 30, 2014.
CGIX: 7.83 (+0.84)
BioNano Genomics Announces The Purchase Of The Irys System By The Wellcome Trust Sanger Institute
PR Newswire - Tue Aug 12, 7:00AM CDT
BioNano Genomics announced today the purchase of an IrysTM System by the Wellcome Trust Sanger Institute, one of the world's leading genome centers, located near Cambridge, UK. The Sanger Institute made the largest single contribution to the gold standard sequence for the Human Genome Project and today is focused on the role of genetics in health and disease. The Sanger Institute purchased BioNano's Irys platform to detect structural variation and complete genomes for various projects including the Cancer Genomics Project, which seeks to develop new ways of detecting rearrangements in cancer samples, and the Parasite Genomics Team, which is sequencing the genomes of parasites that cause malaria and neglected tropical diseases prevalent in the developing world.
CGIX: 7.83 (+0.84)
Cancer Genetics to Report Second Quarter 2014 Financial Results on Thursday, August 14, 2014
GlobeNewswire - Fri Aug 08, 7:56AM CDT
Cancer Genetics, Inc. (Nasdaq:CGIX), an emerging leader in DNA-based cancer diagnostics, announced today that it will report second quarter 2014 financial results on Thursday, August 14, 2014. The Company will issue a press release before the market opens and will host a conference call at 8:30am Eastern Time to discuss the second quarter financial results, the closing of the Gentris acquisition, the proposed FDA regulatory framework, and to answer questions.
CGIX: 7.83 (+0.84)
RedChip Issues Research Update on Cancer Genetics
GlobeNewswire - Thu Aug 07, 11:09AM CDT
RedChip Companies, Inc., today announced it has issued a research profile on Cancer Genetics, Inc. (Nasdaq:CGIX), an emerging leader in DNA-based cancer diagnostics that personalizes the clinical management of difficult-to-diagnose cancers.
CGIX: 7.83 (+0.84)
Circulating Nucleic Acids (CNAs) Based Non-Invasive Cancer Diagnostics: Global Market Report 2014
M2 - Thu Aug 07, 10:39AM CDT
Research and Markets (http://www.researchandmarkets.com/research/4mlqf7/circulating) has announced the addition of the "Circulating Nucleic Acids (CNAs) Based Non-Invasive Cancer Diagnostics: Global Market Report" report to their offering. The aim of this report was to review recent advances in use of circulating cell-free miRNA, DNA and mRNA as novel biomarkers which can be used for the detection and diagnosis of cancer, and the impact on making the ongoing research closer to clinical application. The report will also provide a market analysis of the market value, growth rates, market development as well as examining the dynamics and factors influencing the growth and development of this market. This report also looks at the challenges and potential threats facing the industry players, and the factors influencing the market shares of both the major market suppliers and smaller indigenous manufacturers in local markets. The data collection and forecasting methods used in the preparation of this report are broadly divided into three methods. These are primary data and information gathering, secondary data and information gathering and market share analysis and market forecast prediction. Information and data including estimates on market values, growth rates and market share data were gathered from the methods described and were incorporated into proprietary computer forecasting and market share analysis models. The forecast model was used to derive market estimates for future years. It incorporates a rate factor, which helps determine the speed with which the market develops, which is similar to that observed for markets for other medical products and is adjusted to match historic data for the market under analysis. Key Topics Covered: Executive Summary Chapter 1: Introduction to the Circulating Nucleic Acid Market Report Chapter 2: Background to Circulating Nucleic Acids Chapter 3: Cancer: A Statistical Analysis of the Disease Incidence and Prevalence Chapter 4: CNA Based Cancer Diagnostics Market: Revenue Analysis Chapter 5: CNA Based Cancer Diagnostics Market: Market Share Analysis Chapter 6: Company Profiles - Abbott Laboratories (Abbott Molecular) - Affymetrix Inc - Autogenomics - Becton Dickinson and Company (BD) - Beckmann Coulter, Inc (Danaher Corporation) - bioM?rieux - Cancer Genetics, Inc - Cepheid - Dako (Agilent) - Epigenomics - Hologic Gen-Probe - Illumina - Ipsogen (Qiagen) - Luminex - MolecularMD - Myriad Genetics Laboratories - Novartis Diagnostics - Ortho-Clinical Diagnostics (The Carlyle Group) - Oxford Gene Technology (OGT) - Qiagen N.V. - Roche - Siemens - Sysmex Corporation - Thermo Fisher Scientific - Ventana (Roche) - For more information visit http://www.researchandmarkets.com/research/4m...irculating
ABT: 42.39 (+0.93), MYGN: 36.68 (+1.68), CPHD: 48.14 (+1.58), QGEN: 22.58 (+0.46), DHR: 76.25 (+1.52), HOLX: 24.76 (+0.75), CGIX: 7.83 (+0.84), AFFX: 7.68 (+0.12), NVS: 88.61 (+0.71)
RedChip TV Announces Lineup for This Week's Show on Fox Business and Bloomberg
GlobeNewswire - Tue Aug 05, 3:48PM CDT
RedChip Companies, Inc. ("RedChip" , an international small-cap research, investor relations, and media company, today announced that "The RedChip Money Report: Small Stocks Big Money"
TM) television program will feature three companies on Fox Business nationwide on Tuesday, August 5, 2014 at 10:00 p.m. Pacific (1 a.m. EDT). The show will also air on Bloomberg U.K. Saturday, August 9, 2014 at 12:30 a.m. GMT; on Bloomberg Europe on Sunday, August 10, 2014 at 8:30 a.m. and 3:30 p.m. GMT; and on Bloomberg Asia on Sunday August 10, 2014 at 3:30 p.m. HKT.
TOPS: 1.81 (+0.16), AWK: 50.98 (+0.24), CGIX: 7.83 (+0.84)
Cancer Genetics, Inc. Releases the Only Comprehensive Genomic Test to Diagnose & Stratify the Most Common Form of Leukemia (CLL)
GlobeNewswire - Mon Aug 04, 6:30AM CDT
-- CGI's proprietary genomic test has been CLIA and NYS licensed to stratify CLL and SLL patient into three distinct outcome groups: favorable, intermediate, and unfavorable
CGIX: 7.83 (+0.84)
Coping with Cancer Effectively Using Enhanced Diagnosis and Treatment
GlobeNewswire - Wed Jul 30, 2:45AM CDT
via PRWEB - Cancer Therapy-2014 will be an unique platform, which will bring together the renowned oncologists, scientists and scholars in pursuit of unraveling the mysteries of cancer under one roof. In the Keynote forum of Cancer Therapy-2014 many eminent experts in the field like Prof. Rudolf Wank, Immunotherapy Research Center, Germany; Sudhakar Yakkanti, SRI International, USA will mark their presence. A special session on "Bioactive Natural Products for Cancer Prevention and Therapy" will be chaired by Dr. Anupam Bishayee, Assistant Dean and Chair, American University of Health Sciences. This significant session will feature expertise presentations like "Genistein in prevention and treatment of cancer", "Effect of phytochemicals on breast cancer cells", "Control colorectal cancer" and "Effects of herbs on major cancers".
CGIX: 7.83 (+0.84)
Cancer Genetics, Inc. to Present at the Canaccord Genuity 34th Annual Growth Conference
GlobeNewswire - Tue Jul 22, 7:00AM CDT
Cancer Genetics, Inc. (Nasdaq:CGIX) ("CGI" or the "Company" , an emerging leader in DNA-based diagnostics, today announced that an overview of the Company's business and commercial strategy will be given by CGI's Chief Executive Officer, Panna Sharma, at the Canaccord Genuity 34 Annual Growth Conference, being held in Boston August 13-14, 2014.
CGIX: 7.83 (+0.84)
Cancer Genetics Announces Acquisition of Gentris Corporation, a Leading Global Pharmacogenomics Company, and Increases Contract Backlog to Over $18 Million
GlobeNewswire - Mon Jul 21, 6:45AM CDT
-- Acquisition Adds Contracts With Five of the Top Biopharma Companies Globally
CGIX: 7.83 (+0.84)
Cancer Genetics Inc. Granted Patent for Genomic Probe Set Used in Proprietary Test for Cervical and Other HPV-Associated Cancers
GlobeNewswire - Tue Oct 21, 6:59AM CDT
> Issuance of patent 8,865,882 covers four probe set used in CGI's proprietary FISH-based HPV-Associated Cancer Test (FHACT(R))
CGIX: 7.83 (+0.84)
Cancer Genetics Inc. Announces Collaboration With Leading Oncology Researchers at Columbia University to Identify Genomic Signatures, Biomarkers and Novel Treatments for MDS and AML
GlobeNewswire - Mon Oct 13, 6:45AM CDT
> The collaboration will result in a novel, next-generation sequencing based panel for the improved diagnosis and prognosis of Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)
CGIX: 7.83 (+0.84)
Global Genetic Testing Market - Industry Analysis And Market Forecast 2014-2020
PR Newswire - Thu Oct 09, 2:50PM CDT
Genetic testing is the analysis of genes, chromosomes, or proteins to help predict the risk of disease, identify carriers (individuals who do not have the disease but have a copy of the disease gene) of disease, diagnose disease, or determine the likely course of a disease. Cytogenetics, Molecular Genetics, Cancer Genetics, Prenatal Screening and Prenatal diagnosis are type of genetic tests that involves examining a person's genetic material taken from cells in a sample of blood or, occasionally, from other body fluids or tissues.
CGIX: 7.83 (+0.84)
Cancer Genetics Inc. to Provide Updates About the Company's Portfolio of Targeted Molecular Diagnostics at Analyst Day on September 25, 2014
GlobeNewswire - Wed Sep 24, 6:45AM CDT
Cancer Genetics Inc. (Nasdaq:CGIX) ("CGI" or "the Company"
, an emerging leader in DNA-based cancer diagnostics, today released an agenda for its upcoming Analyst Day, to be held Thursday, September 25 in Raleigh, North Carolina. CGIX: 7.83 (+0.84)
Cancer Genetics, Inc. and Beth Israel Deaconess Medical Center Enter Into Collaboration to Correlate Genomic Profiles to Patient Outcome in Diffuse Large B-Cell Lymphoma
GlobeNewswire - Tue Sep 23, 6:45AM CDT
-- Study will correlate genetic markers to outcome in ~200 patients with diffuse large B-cell lymphoma (DLBCL), the most common form of non-Hodgkin lymphoma.
CGIX: 7.83 (+0.84)
Cancer Genetics, Inc. to Present at Aegis Healthcare and Technology Conference on Thursday, September 11, 2014
GlobeNewswire - Wed Sep 10, 6:59AM CDT
Cancer Genetics, Inc. (Nasdaq:CGIX) ("CGI" or "The Company"
, an emerging leader in DNA-based cancer diagnostics, announced today that Panna Sharma will present at the Aegis Healthcare and Technology Conference on Thursday, September 11, 2014 at 8:30 am Pacific Daylight Time (11:30 am EDT). CGIX: 7.83 (+0.84)
Cancer Genetics' Proprietary IVD for Cervical Cancer, FHACT(R), Receives CE
GlobeNewswire - Tue Sep 02, 7:15AM CDT
- Cancer Genetics, Inc. (Nasdaq:CGIX) ("CGI" or "The Company"
, an emerging leader in DNA-based cancer diagnostics, announced today that their proprietary DNA-probe based test for cervical cancer (FHACT(R)) has received the CE Marking. CGIX: 7.83 (+0.84)
Cancer Genetics' Proprietary Genomic Diagnostic Tests Added to National Institutes of Health's Genetic Testing Registry
GlobeNewswire - Wed Aug 27, 6:59AM CDT
-- Online database allows clinicians and patients to search for genetic and genomic tests by disease state
CGIX: 7.83 (+0.84)
Cancer Genetics, Inc. and Leading Pathologist From Keck Medicine of USC Collaborate to Evaluate and Optimize Genomic Panel for Lymphoma
GlobeNewswire - Mon Aug 25, 7:30AM CDT
-- Collaboration will identify and evaluate new genomic markers for most common form of non-Hodgkin's lymphoma
CGIX: 7.83 (+0.84)
Cancer Genetics Inc. Completes Acquisition of BioServe India, a Premier Genomics and Next-Generation Sequencing Company
GlobeNewswire - Sun Aug 17, 11:00PM CDT
-- Cancer Genetics Now Positioned to Participate in High-Growth Indian Diagnostics Market, Where More Than 1 Million New Cancer Cases Are Diagnosed Each Year
CGIX: 7.83 (+0.84)
Cancer Genetics Reports Second Quarter 2014 Financial Results
GlobeNewswire - Thu Aug 14, 6:05AM CDT
Cancer Genetics, Inc. (Nasdaq:CGIX), an emerging leader in DNA-based cancer diagnostics, announced today financial results for the second quarter and six months ended June 30, 2014.
CGIX: 7.83 (+0.84)
BioNano Genomics Announces The Purchase Of The Irys System By The Wellcome Trust Sanger Institute
PR Newswire - Tue Aug 12, 7:00AM CDT
BioNano Genomics announced today the purchase of an IrysTM System by the Wellcome Trust Sanger Institute, one of the world's leading genome centers, located near Cambridge, UK. The Sanger Institute made the largest single contribution to the gold standard sequence for the Human Genome Project and today is focused on the role of genetics in health and disease. The Sanger Institute purchased BioNano's Irys platform to detect structural variation and complete genomes for various projects including the Cancer Genomics Project, which seeks to develop new ways of detecting rearrangements in cancer samples, and the Parasite Genomics Team, which is sequencing the genomes of parasites that cause malaria and neglected tropical diseases prevalent in the developing world.
CGIX: 7.83 (+0.84)
Cancer Genetics to Report Second Quarter 2014 Financial Results on Thursday, August 14, 2014
GlobeNewswire - Fri Aug 08, 7:56AM CDT
Cancer Genetics, Inc. (Nasdaq:CGIX), an emerging leader in DNA-based cancer diagnostics, announced today that it will report second quarter 2014 financial results on Thursday, August 14, 2014. The Company will issue a press release before the market opens and will host a conference call at 8:30am Eastern Time to discuss the second quarter financial results, the closing of the Gentris acquisition, the proposed FDA regulatory framework, and to answer questions.
CGIX: 7.83 (+0.84)
RedChip Issues Research Update on Cancer Genetics
GlobeNewswire - Thu Aug 07, 11:09AM CDT
RedChip Companies, Inc., today announced it has issued a research profile on Cancer Genetics, Inc. (Nasdaq:CGIX), an emerging leader in DNA-based cancer diagnostics that personalizes the clinical management of difficult-to-diagnose cancers.
CGIX: 7.83 (+0.84)
Circulating Nucleic Acids (CNAs) Based Non-Invasive Cancer Diagnostics: Global Market Report 2014
M2 - Thu Aug 07, 10:39AM CDT
Research and Markets (http://www.researchandmarkets.com/research/4mlqf7/circulating) has announced the addition of the "Circulating Nucleic Acids (CNAs) Based Non-Invasive Cancer Diagnostics: Global Market Report" report to their offering. The aim of this report was to review recent advances in use of circulating cell-free miRNA, DNA and mRNA as novel biomarkers which can be used for the detection and diagnosis of cancer, and the impact on making the ongoing research closer to clinical application. The report will also provide a market analysis of the market value, growth rates, market development as well as examining the dynamics and factors influencing the growth and development of this market. This report also looks at the challenges and potential threats facing the industry players, and the factors influencing the market shares of both the major market suppliers and smaller indigenous manufacturers in local markets. The data collection and forecasting methods used in the preparation of this report are broadly divided into three methods. These are primary data and information gathering, secondary data and information gathering and market share analysis and market forecast prediction. Information and data including estimates on market values, growth rates and market share data were gathered from the methods described and were incorporated into proprietary computer forecasting and market share analysis models. The forecast model was used to derive market estimates for future years. It incorporates a rate factor, which helps determine the speed with which the market develops, which is similar to that observed for markets for other medical products and is adjusted to match historic data for the market under analysis. Key Topics Covered: Executive Summary Chapter 1: Introduction to the Circulating Nucleic Acid Market Report Chapter 2: Background to Circulating Nucleic Acids Chapter 3: Cancer: A Statistical Analysis of the Disease Incidence and Prevalence Chapter 4: CNA Based Cancer Diagnostics Market: Revenue Analysis Chapter 5: CNA Based Cancer Diagnostics Market: Market Share Analysis Chapter 6: Company Profiles - Abbott Laboratories (Abbott Molecular) - Affymetrix Inc - Autogenomics - Becton Dickinson and Company (BD) - Beckmann Coulter, Inc (Danaher Corporation) - bioM?rieux - Cancer Genetics, Inc - Cepheid - Dako (Agilent) - Epigenomics - Hologic Gen-Probe - Illumina - Ipsogen (Qiagen) - Luminex - MolecularMD - Myriad Genetics Laboratories - Novartis Diagnostics - Ortho-Clinical Diagnostics (The Carlyle Group) - Oxford Gene Technology (OGT) - Qiagen N.V. - Roche - Siemens - Sysmex Corporation - Thermo Fisher Scientific - Ventana (Roche) - For more information visit http://www.researchandmarkets.com/research/4m...irculating
ABT: 42.39 (+0.93), MYGN: 36.68 (+1.68), CPHD: 48.14 (+1.58), QGEN: 22.58 (+0.46), DHR: 76.25 (+1.52), HOLX: 24.76 (+0.75), CGIX: 7.83 (+0.84), AFFX: 7.68 (+0.12), NVS: 88.61 (+0.71)
RedChip TV Announces Lineup for This Week's Show on Fox Business and Bloomberg
GlobeNewswire - Tue Aug 05, 3:48PM CDT
RedChip Companies, Inc. ("RedChip"
, an international small-cap research, investor relations, and media company, today announced that "The RedChip Money Report: Small Stocks Big Money" TM) television program will feature three companies on Fox Business nationwide on Tuesday, August 5, 2014 at 10:00 p.m. Pacific (1 a.m. EDT). The show will also air on Bloomberg U.K. Saturday, August 9, 2014 at 12:30 a.m. GMT; on Bloomberg Europe on Sunday, August 10, 2014 at 8:30 a.m. and 3:30 p.m. GMT; and on Bloomberg Asia on Sunday August 10, 2014 at 3:30 p.m. HKT. TOPS: 1.81 (+0.16), AWK: 50.98 (+0.24), CGIX: 7.83 (+0.84)
Cancer Genetics, Inc. Releases the Only Comprehensive Genomic Test to Diagnose & Stratify the Most Common Form of Leukemia (CLL)
GlobeNewswire - Mon Aug 04, 6:30AM CDT
-- CGI's proprietary genomic test has been CLIA and NYS licensed to stratify CLL and SLL patient into three distinct outcome groups: favorable, intermediate, and unfavorable
CGIX: 7.83 (+0.84)
Coping with Cancer Effectively Using Enhanced Diagnosis and Treatment
GlobeNewswire - Wed Jul 30, 2:45AM CDT
via PRWEB - Cancer Therapy-2014 will be an unique platform, which will bring together the renowned oncologists, scientists and scholars in pursuit of unraveling the mysteries of cancer under one roof. In the Keynote forum of Cancer Therapy-2014 many eminent experts in the field like Prof. Rudolf Wank, Immunotherapy Research Center, Germany; Sudhakar Yakkanti, SRI International, USA will mark their presence. A special session on "Bioactive Natural Products for Cancer Prevention and Therapy" will be chaired by Dr. Anupam Bishayee, Assistant Dean and Chair, American University of Health Sciences. This significant session will feature expertise presentations like "Genistein in prevention and treatment of cancer", "Effect of phytochemicals on breast cancer cells", "Control colorectal cancer" and "Effects of herbs on major cancers".
CGIX: 7.83 (+0.84)
Cancer Genetics, Inc. to Present at the Canaccord Genuity 34th Annual Growth Conference
GlobeNewswire - Tue Jul 22, 7:00AM CDT
Cancer Genetics, Inc. (Nasdaq:CGIX) ("CGI" or the "Company"
, an emerging leader in DNA-based diagnostics, today announced that an overview of the Company's business and commercial strategy will be given by CGI's Chief Executive Officer, Panna Sharma, at the Canaccord Genuity 34 Annual Growth Conference, being held in Boston August 13-14, 2014. CGIX: 7.83 (+0.84)
Cancer Genetics Announces Acquisition of Gentris Corporation, a Leading Global Pharmacogenomics Company, and Increases Contract Backlog to Over $18 Million
GlobeNewswire - Mon Jul 21, 6:45AM CDT
-- Acquisition Adds Contracts With Five of the Top Biopharma Companies Globally
CGIX: 7.83 (+0.84)
